Search

Your search keyword '"Edward A. Galen"' showing total 5 results
Start Over Author "Edward A. Galen"
5 results on '"Edward A. Galen"'

1. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

Author

Stuart C. Gordon, Rvikumar Vemuru, Mark Eisner, Jay Cowan, James Ehrlich, Alain Ades, Clifford A. Brass, Micheal David Bernstein, Steve Chen, Donald Hillebrand, Donald Wadland, Lyle Shlager, C. Smith, Lou Gelrud, Mark Levstik, Helen Wong, Stephen A. Harrison, Andrew Nelson, Raj Bhandari, David Dies, Mordechai Rabinovitz, Edward A. Galen, B. Freilich, K. Digregorio, Curt Hagendom, Thomas Hargrave, Paul Bermanski, David Maccini, Samuel B. Ho, Ronald Pruitt, Terence Reisman, Thomas Allen, Robert S. Brown, Michael Cox, David Schulman, Ramsey Cheung, Fred Kilby, J. Lynn Cochran, Thomas McDonald, James Thornton, John Jolley, John Serini, Albert D. Min, Fredrich Loura, Lino Deguzman, Luis Marsano, Robert Finkel, Helen S. Te, Michael G Rahmin, Mark Jonas, Kip Lyche, Jean Luc Szpakowski, George Abraham, Alex D. Lee, Pabak Mukhopadhyay, Firdous Siddiqui, Robert Strauss, William Kaplan, Michael Ryan, Eliot Godofsky, Stephen J. Lanspa, Lawton Shick, Jose Franco, Louis Griffel, Rise Stribling, Avanish Aggarwal, Clive Albert, Thomas Rosenfield, Rockford Yapp, Vijay Balan, Arthur Berman, Nezam H. Afdhal, Maurice Cerulli, Paul Yudelman, Robert Herring, Donate Ricci, Michael Henry, Michael Bloom, Daniel Meline, Barry Migicovsky, Peter Varunok, Peter W Gardner, Gerald Siciliano, Natarjan Bala, Craig J. Peine, P. Kwo, Thomas Noble, David F. Stein, Thuan T. Nguyen, Geoffrey Zucker, Julie E Spivack, John Kichner, Robert G. Gish, Michael Fried, Murali Shankar, Norman Gitlin, James E. Nelson, David Hurwich, Darrell Schwertner, Ronald Wasserman, Douglas D. Dalke, Thai Van Pham, Geronimo Sahagun, Norah A. Terrault, Naoky Tsai, Steven Han, Tarek Hassanein, Thomas Sepe, Seth Richter, Howard Paul Monsour, Micheal Lyons, R. Agrawal, Bennett Cecil, Joseph Polito, Douglas Levin, James Srour, Allan Weston, Larry Weprin, Raymond Kenny, Edward Lebovics, Michael Demicco, Terry Box, Kenneth Diamond, Lawrence Kim, Stephen Kelly, Martin Black, Jeffrey Fenyves, Ellen Shaw, Raymond A. Rubin, James E. Cox, Franco Felizarta, John E. Gross, Ira Lobis, David H. Van Thiel, Bonnie Bock, Lawrence Stein, James D. Lewis, Steven Palley, Ronald Rinker, Joanna Ready, Vinod K. Rustgi, Michael Epstein, David H Berman, Gary Matusow, Walid Baddoura, Gerond Lake-Bakaar, John S. Goff, Scott Wiesen, Neil Brodsky, Fredric Regenstein, Arnold Levin, Bhupinder S. Anand, Stephen Esposito, K. Rajender Reddy, Lisa Ozick, Adil E. Wakil, Karl Esrason, Pierre Nader, David Nunes, David Feldman, K. Ganeshappa, Alan Fixelle, Martha Ghosh, Douglas Brouillette, Victor Araya, Hillel Tobias, David Pound, Louis R. Lambiase, S. Lawrence Rothman, Mark J. Murphy, Jonathan David, James Levin, Steve Carlson, Nathan Kam, Michael S. Dragutsky, Trong Nguyen Tuan, Graham Woolf, Whit Knapple, Donna Goldman, Kenneth R. DeVault, Simon Cofrancesco, Mitchell L. Shiffman, Charles Bedard, Paul Y. Kwo, Rodger Perez, Steven L. Flamm, Keith Tolman, Hulya Levendoglu, Timothy Cavacini, Robert Reindollar, Vance VanDrake, Donald M. Jensen, David Winston, Robert A. Levine, Robert Manning, John R. Lake, John J. Santoro, Scott Becker, Mary Pat Pauly, John M. Vierling, Joseph DePasquale, Jorge Herrera, Diana Sylvestre, Natarajan Ravendhran, Mark Smith, Kevin Dye, M. Davis, Frank Klion, Kevin Behrle, Alan Epstein, William Lyles, Brian K. Hudes, Greg Galler, David I. Bernstein, Jonathon Jensen, Jeffery Cooley, Thomas J. Layden, Carl D'Angelo, Fredric D. Gordon, Myron Brand, David Gabbazaideh, Leon Rigberg, Neville R. Pimstone, Jonathan McCone, Ira M. Jacobson, Tim M Jenkins, John W. King, Harry Matossian, William A. Ross, and Rudra Rai

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Genotype, Hepatitis C virus, Alpha interferon, Hepacivirus, Interferon alpha-2, medicine.disease_cause, Antiviral Agents, Gastroenterology, Polyethylene Glycols, chemistry.chemical_compound, Pegylated interferon, Internal medicine, Ribavirin, medicine, Humans, Prospective Studies, Interferon alfa, Aged, Dose-Response Relationship, Drug, Hepatology, business.industry, Body Weight, Interferon-alpha, Middle Aged, Hepatitis C, Recombinant Proteins, Surgery, Treatment Outcome, chemistry, RNA, Viral, Peginterferon alfa-2b, Drug Therapy, Combination, Female, business, Viral load, medicine.drug
Abstract

This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with chronic hepatitis C. Patients (n = 5027) were randomly assigned to receive PEG-IFN alfa-2b 1.5 μg/kg/week plus flat-dose (800 mg/day) or weight-based (800-1400 mg/day) RBV for 48 weeks (patients with genotype 1, 4, 5, or 6) and for 24 or 48 weeks (genotype 2/3 patients). Primary end point was sustained virologic response (undetectable [

Published
2007

2. Continuous combination therapy has superior viral clearance compared to standard combination therapy-A multicenter, randomized trial

Author

Eric Lawitz, Paul Warfield, John J. Jolley, Thaun Nguyen, Mark Jeffries, Kenneth Diamond, Avanish Aggarwal, Bahri Billir, Harry Matossian, David M. James, Shailesh C. Kadakia, and Edward A. Galen

Subjects
medicine.medical_specialty, Hepatology, Randomized controlled trial, Combination therapy, business.industry, law, Internal medicine, Gastroenterology, Medicine, business, law.invention
Published
2001

3. Chronic non-A, non-B hepatitis: Ultrastructural and serologic studies

Author

Robert L. Carithers, Guy A. Cabral, Thomas J. Sobieski, Edward A. Galen, Francine Marciano-Cabral, and Karen L. Rublee

Subjects
Male, Counterimmunoelectrophoresis, Cytoplasm, Pathology, medicine.medical_specialty, Hepatitis, Viral, Human, Biopsy, Immunoelectron microscopy, Antigen-Antibody Complex, Serology, medicine, Humans, Hepatitis B Antibodies, Cell Nucleus, Hepatitis, Hepatology, biology, business.industry, Middle Aged, Precipitin, medicine.disease, Hepatitis C, Liver, biology.protein, Ultrastructure, Antibody, business
Abstract

Liver biopsies from five patients with chronic non-A, non-B (NANB) hepatitis were examined by electron microscopy for hepatocellular alterations. Circular fused membranes were observed within the cytoplasm of hepatocytes of four of the patients. Aggregates of intranuclear particles, measuring 22 +/- 2 nm in diameter, were also seen in two of the biopsies in which fused membranes were identified. Sera of all five patients formed precipitin lines detectable by counterimmunoelectrophoresis when reacted with serum from an individual convalescent from posttransfusion NANB hepatitis. Using this convalescent serum as an antibody source, complexes of 22 +/- 2 nm particles were identified in three of the chronic patient sera by immunoelectron microscopy. These observations suggest that at last one of the agents responsible for NANB hepatitis elicits both nuclear and cytoplasmic modifications. Furthermore, the 22 +/- 2 nm particles circulating in the sera of the chronic NANB patients may represent components related to NANB hepatitis agent.

Published
1981

4. Nuclear changes in hepatocytes of patients with non-A, non-B hepatitis

Author

Edward A. Galen, Guy A. Cabral, Robert L. Carithers, M. Patterson, and Francine Marciano-Cabral

Subjects
Hepatitis, Pathology, medicine.medical_specialty, Hepatology, Gastroenterology, medicine, Non b hepatitis, Biology, medicine.disease, Virology
Abstract

Experimental non-A, non-B hepatitis infection has been shown to produce two distinct ultrastructural changes in chimpanzees: intranuclear particles and intracytoplasmic tubular structures. We report our observations of intranuclear particles in humans with acute non-A, non-B hepatitis. These particles appear to be specific for at least one type of non-A, non-B hepatitis.

Published
1981

5. Determination of immunoglobulin M antibodies against hepatitis B core antigen and hepatitis A virus by reorienting sucrose gradient high-speed centrifugation for diagnosis of acute viral-hepatitis

Author

Edward A. Galen, Robert L. Carithers, Mario R. Escobar, and Paul D. Swenson

Subjects
Microbiology (medical), Hepatitis, Viral, Human, viruses, Radioimmunoassay, Antibodies, Viral, Antigen, Centrifugation, Density Gradient, Medicine, Hepatovirus, Hepatitis B Antibodies, Hepatitis, biology, business.industry, virus diseases, Hepatitis A, Hepatitis B, medicine.disease, Hepatitis B Core Antigens, Hepatitis C, Virology, digestive system diseases, Immunoglobulin M, Immunology, biology.protein, Antibody, business, Viral hepatitis, Research Article
Abstract

Immunoglobulin M (IgM) antibodies against hepatitis B core antigen (anti-HBc) and hepatitis A virus (anti-HAV) were determined in 41 cases of acute viral hepatitis. In sera positive for anti-HBc or anti-HAV, IgM was separated from IgG by reorienting sucrose gradient high-speed centrifugation, and the IgG- and IgM-containing serum fractions were tested for the presence of specific antibody by radioimmunoassay. At the onset of illness, 4 of the 41 cases were classified as hepatitis A, 31 were hepatitis B, and 6 were non-A, non-B hepatitis, based on the results of these tests and of assays for hepatitis B surface antigen and antibody and hepatitis B e antigen and antibody. Fourteen of these 41 patients (34%) required IgM anti-HBc or IgM anti-HAV testing or both for appropriate classification. IgM anti-HBc persisted for at least 7 weeks after onset but no longer than 17 weeks in all patients tested with transient hepatitis B surface antigen-positive acute hepatitis. IgM anti-HAV persisted up to but not longer than 62 days in the patients with hepatitis A. Therefore, IgM anti-HBc and IgM anti-HAV determinants are valuable tools for the differential diagnosis of acute A, B, and non-A, non-B hepatitis.

Published
1981

Catalog

Books, media, physical & digital resources
See catalog results